Lazard Asset Management LLC Genmab A/S Transaction History

Lazard Asset Management LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$27.94 - $35.44 $30,650 - $38,877	-1,097 Reduced 55.52%	879 $27,000
Q2 2023 Aug 14, 2023	BUY	$37.4 - $42.94 $8,751 - $10,047	234 Added 13.43%	1,976 $75,000
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $2,501 - $3,482	-74 Reduced 4.07%	1,742 $73,000
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $20,519 - $243,220	651 Added 55.88%	1,816 $56,000
Q2 2022 Aug 09, 2022	SELL	$26.83 - $38.57 $13,629 - $19,593	-508 Reduced 30.36%	1,165 $36,000
Q1 2022 May 13, 2022	BUY	$30.95 - $39.68 $6,406 - $8,213	207 Added 14.12%	1,673 $59,000
Q4 2021 Feb 09, 2022	BUY	$35.87 - $47.12 $7,030 - $9,235	196 Added 15.43%	1,466 $56,000
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $6,024 - $7,064	145 Added 12.89%	1,270 $54,000
Q2 2021 Aug 12, 2021	BUY	$32.88 - $44.57 $6,641 - $9,003	202 Added 21.89%	1,125 $45,000
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $2,566 - $3,685	-83 Reduced 8.25%	923 $30,000
Q4 2020 Feb 11, 2021	SELL	$33.66 - $40.76 $5,621 - $6,806	-167 Reduced 14.24%	1,006 $40,000
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $8,036 - $9,399	-243 Reduced 17.16%	1,173 $42,000
Q2 2020 Aug 13, 2020	SELL	$20.05 - $33.89 $33.1 Million - $56 Million	-1,652,241 Reduced 99.91%	1,416 $47,000
Q1 2020 May 14, 2020	SELL	$17.15 - $25.22 $452,416 - $665,303	-26,380 Reduced 1.57%	1,653,657 $35 Million
Q4 2019 Feb 13, 2020	SELL	$18.88 - $24.14 $265,905 - $339,987	-14,084 Reduced 0.83%	1,680,037 $37.5 Million
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $30.5 Million - $36.2 Million	1,694,121 New	1,694,121 $34.3 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.